Q1 Earnings Estimate for Immunic Issued By Leerink Partnrs

Key Points

• Leerink Partners estimates Immunic will report a Q1 2026 EPS of ($0.08), with a full-year consensus of ($0.94) EPS.
• The company recently missed its quarterly earnings expectation, reporting ($0.20) EPS compared to a consensus of ($0.18).
• Immunic's stock has an average target price of $7.50, with most analysts rating it as a buy or outperform.

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Analysts at Leerink Partnrs issued their Q1 2026 earnings per share (EPS) estimates for Immunic in a research note issued to investors on Thursday, August 7th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings of ($0.08) per share for the quarter. The consensus estimate for Immunic's current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunic's Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.06) EPS and Q4 2026 earnings at ($0.05) EPS.

Several other research analysts have also recently issued reports on IMUX. William Blair reaffirmed an "outperform" rating on shares of Immunic in a research report on Friday, May 16th. B. Riley reaffirmed a "buy" rating and set a $5.00 target price (down previously from $6.00) on shares of Immunic in a research report on Friday, May 23rd. D. Boral Capital reaffirmed a "buy" rating and set a $10.00 target price on shares of Immunic in a research report on Friday, August 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Immunic in a research report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, five have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $7.50.

Immunic Trading Down 1.3%

Shares of NASDAQ:IMUX traded down $0.01 during mid-day trading on Monday, hitting $0.91. 511,417 shares of the company traded hands, compared to its average volume of 1,237,195. The stock has a market cap of $89.28 million, a P/E ratio of -0.74 and a beta of 1.39. Immunic has a 12-month low of $0.56 and a 12-month high of $2.11. The stock has a 50-day moving average price of $0.85 and a two-hundred day moving average price of $0.97.

Immunic (NASDAQ:IMUX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02).

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Aberdeen Group plc grew its stake in Immunic by 678.1% in the 2nd quarter. Aberdeen Group plc now owns 8,243,941 shares of the company's stock valued at $5,750,000 after purchasing an additional 7,184,457 shares during the period. Focus Partners Wealth grew its stake in Immunic by 19.1% in the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company's stock valued at $2,816,000 after purchasing an additional 415,104 shares during the period. 683 Capital Management LLC grew its stake in Immunic by 28.6% in the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company's stock valued at $981,000 after purchasing an additional 200,000 shares during the period. Millennium Management LLC grew its stake in Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company's stock valued at $580,000 after purchasing an additional 479,846 shares during the period. Finally, Renaissance Technologies LLC grew its stake in Immunic by 45.6% in the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock valued at $567,000 after purchasing an additional 177,542 shares during the period. Institutional investors own 51.82% of the company's stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.